The Cystic Fibrosis Buyers Club, set up in the UK by parents of children with the condition, is hoping to help some patients import generic versions of Vertex’s cystic fibrosis drug Orkambi (ivacaftor/lumacaftor) from Latin America. Health advocates hope the move could lead to a compulsory license for Orkambi and believe that buyers clubs could be used more frequently in response to medicine prices that prohibit access to medicines.
UK Buyers Club To Get Lower Cost Versions Of Vertex’s CF Drugs
A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS. Some commentators think such clubs may become more common.
More from Europe
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
More from Geography
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.